Adjusted earnings reached $2.19 per share, outperforming analyst forecasts by 26¢. Revenue also surpassed projections of $2.35 billion. Sales of da Vinci systems rose 17% year over year, with 395 systems placed globally during the quarter, up from 341 in the same period last year. Notably, placements of the new da Vinci 5 nearly tripled from 70 to 180 units.

CEO Dave Rosa attributed the strong performance to continued adoption of both legacy and next-generation platforms, emphasizing the company’s focus on improving outcomes, expanding access, and reducing care costs. Looking ahead, Intuitive expects da Vinci procedure volumes to grow 15.5–17% in 2025, with non-GAAP gross margins of 66–67%, including a 1% revenue impact from tariffs.

Follow MEDWIRE.AI for surgical robotics insights and market updates.

Dr. Sudhir Srivastava, company chair and CEO, remotely performed an atrial septal defect closure from IRCAD’s headquarters in Strasbourg, France, while the patient was at Sri Aurobindo Institute of Medical Sciences in Indore, India—a distance of over 4,000 miles. The procedure took place during the Society of Robotic Surgery Annual Meeting and featured imperceptible latency and precision control, showcasing Mantra 3’s advanced capabilities.

The Mantra 3 platform supports multiple specialties with modular 3D vision, an open-console design, and machine learning enhancements for safety and efficiency. SS Innovations plans FDA submission this month and hopes for approval later in 2025.

Dr. Srivastava said the milestone marks a step toward democratizing access to complex cardiac care worldwide.

Follow MEDWIRE.AI for updates on robotic surgery and telemedicine advancements.

This marks the first robotic-driven LigaSure instrument, enhancing vessel sealing and cutting of vessels up to 7 mm with minimal thermal spread. Hugo now operates in 30 countries across five continents, with FDA review ongoing for a U.S. urology indication.

Follow MEDWIRE.AI for surgical robotics market updates.

Proximie will integrate its cloud-based Software Development Kit (SDK) into Telos, allowing real-time sharing of audio, video and telemetry data during procedures. The collaboration builds on Proximie’s recent partnerships with Olympus and Distalmotion to expand its reach in digital surgery.

Imperative Care’s CEO Fred Khosravi says the goal is to close the significant treatment gap, noting that around 80% of eligible stroke patients in the U.S. do not receive thrombectomy care.

Follow MEDWIRE.AI for robotic stroke treatment developments.

NanoWrist instruments—scissors and forceps—are the first fully wristed robotic tools designed for precise dissection and delicate tissue manipulation in open microsurgery, aiding procedures like vessel preparation and tissue resection.

Synaptix offers data-driven visual enhancements and workflow integration, aiming to reduce variability, streamline setup, and improve autonomy in the operating room.

MMI received FDA de novo clearance for Symani in April 2024. The limited European launch precedes full commercial release.

CEO Mark Toland emphasized these advancements mark critical “firsts” beyond anastomosis, enhancing precision and control across more open microsurgical procedures.

Follow MEDWIRE.AI for robotic surgery and digital health updates.

Monogram develops semi- and fully autonomous robotic technologies designed to complement Zimmer Biomet’s flagship Rosa orthopedic robotic platform. The acquisition aims to position Zimmer Biomet as the first orthopedic company offering fully autonomous surgical robots, with plans to integrate Monogram’s technology into its portfolio.

Monogram’s mBôs system, a CT-based semi-autonomous robotic solution for total knee arthroplasty (TKA), received FDA 510(k) clearance earlier this year, with a fully autonomous version under development. Zimmer Biomet expects to commercialize these innovations alongside its existing Rosa platform, which has nearly 2,000 installations worldwide.

CEO Ivan Tornos emphasized the deal’s strategic value, aiming to provide a comprehensive robotic ecosystem tailored to surgeon preferences and advancing orthopedic surgery’s future.

Analysts noted the deal complements Zimmer Biomet’s existing offerings but raised questions about the potential impact on Rosa’s market positioning. Some view the acquisition as providing options across robotic autonomy levels, while others wonder if it signals a shift toward replacing Rosa in the long term.

The transaction is expected to close by the end of 2025, financed through cash and debt, with neutral adjusted EPS impact through 2027 and accretive effects projected thereafter.

Follow MEDWIRE.AI for orthopedic robotics and medtech mergers updates.

Stark leverages LivsMed’s ArtiSential handheld robotics technology, offering 90 degrees of articulation and a small footprint, making advanced robotic surgery more agile and cost-effective for hospitals with limited space or budget. Surgeons from City of Hope National Medical Center remotely performed procedures, including a cholecystectomy and partial liver resection, on a porcine model.

LivsMed aims to democratize access to advanced surgical care globally by combining affordable hardware with Sovato’s telepresence workflows and networks. CEO Jung Joo Lee says the goal is to make robotic surgery practical and accessible for every hospital and patient, regardless of location.

Follow MEDWIRE.AI for more on telesurgery and next-gen robotic innovations.

The partnership highlights include a remote teleoperation demo showcased at the Surgical Robotics Society Annual Meeting, allowing users to control a Kinova robotic arm from 3,000 miles away via a haptic interface.

“This partnership accelerates innovation in medical robotics, helping customers bring advanced, connected solutions to market with confidence,” said François Boucher, Kinova.

Follow MEDWIRE.AI for updates on medical robotics and AI integration.

The da Vinci 5 features over 150 enhancements, including force feedback technology, improved 3D vision, advanced tremor and vibration control, and an ergonomic surgeon console. The system received FDA clearance last year and began its U.S. commercial rollout earlier in 2025.

“We’re proud to bring da Vinci 5 to European healthcare systems, offering advanced capabilities that improve outcomes, efficiency, and surgical insights,” said CEO Dave Rosa.

Follow MEDWIRE.AI for updates on surgical robotics and innovation.

The approvals cover the platform’s new active Wi-Fi and 5G connectivity, enabling seamless data exchange with Moon Surgical’s cloud-based Maestro Insights platform. This platform provides surgical teams with procedural insights and tools to track utilization and performance at individual and facility levels.

Additionally, Moon Surgical received clearance for a Predetermined Change Control Plan (PCCP) for its AI-powered ScoPilot product. ScoPilot enables intuitive laparoscope control by translating surgeon instrument movements in real time. The PCCP allows the company to safely build, test, and deploy future updates more rapidly.

“Connectivity unlocks a new layer of value for our customers,” said CEO Anne Osdoit. Chief Strategy Officer Jeff Alvarez called the PCCP clearance “a pivotal moment for Physical AI” and a catalyst for accelerated innovation.

Follow MEDWIRE.AI for surgical robotics and AI in healthcare updates.